Vivos Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Vivos Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Streeterville Capital LLC, along with affiliated entities, has reported beneficial ownership of 1,812,031 shares, representing 9.3% of Vivos Therapeutics, Inc. common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 8.27% of Vivos Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
Dawei Luo has filed a Schedule 13G, revealing a passive beneficial ownership of 8.52% of Vivos Therapeutics Inc.'s common stock, totaling 572,016 shares.